EGFR expression and downstream signaling pathways have shown positive correlations with Glut1 expression and membrane localization in lung cancer [54], pancreatic cancer tissue [55, 56], and triple-negative breast cancer (TNBC) [57], suggesting that TKI-sensitive cancer cells employ passive glucose transporters to engulf glucose and that downregulation of these transporters may account for the anticancer activity of TKIs. This evidence concerns the gene SLC2A1 and lung carcinoma.